Transcript Highlights:

• Opioid treatment programs provide medication for the treatment of opioid use disorder, as well as other
• state opioid crisis, which sadly in 2024 killed over 2,400 Washingtonians.
• Opioid treatment programs are often the first line of defense in addressing the opioid crisis at the
• This is called preventing duplicate discounts.
• First, it prevents manufacturers from unilaterally changing how 340B works.

Summary: The committee first heard House Bill 2437, which would put the Department of Health’s authority to accredit opioid treatment programs into statute and allow the department to set a fee to cover the cost of those services. The prime sponsor and DOH said the bill would preserve a service that is especially important to tribal and rural providers and would be self-sustaining rather than supported by the general fund. Members asked about the relationship between DOH and HCA and whether the bill would duplicate existing authority; staff and the department said DOH already performs the accrediting role and the bill mainly formalizes that authority and fee-setting power. Public testimony on the bill was then closed. The committee then held an extensive work session on the federal 340B drug pricing program and later opened public testimony on House Bill 2145, which would prohibit manufacturers, distributors, and third-party logistics providers from restricting 340B drug acquisition or delivery and from requiring claims or utilization data as a condition of access. Committee staff and NCSL gave background on how 340B works, recent growth in the program, contract pharmacy issues, and state efforts in other jurisdictions. Testimony on HB 2145 was sharply divided: hospitals, community health centers, tribal representatives, contract pharmacies, and labor groups said the bill would protect safety-net providers, rural access, HIV and behavioral health services, and tribal programs from manufacturer restrictions; business groups, pharmaceutical companies, and employer coalitions argued the program has expanded beyond its original intent, lacks transparency, shifts costs to employers and taxpayers, and should be addressed through federal reform instead. No vote was taken in the excerpt. Finally, the committee heard House Bill 2155, which would bar non-human entities from using nursing titles such as RN, APRN, or LPN or otherwise implying they are licensed nurses. The prime sponsor said the bill is intended to protect patients from being misled by AI systems and to preserve transparency and public safety as health care technology expands. The Washington State Nurses Association testified in support, saying AI can be useful but should not replace nurses or be presented as a licensed professional. A member asked about enforcement and liability, and staff said they would follow up on those details.

Transcript Highlights:

• Today we will hear testimony on 14 bills related to insurance, parity, and opioids.
• Today we will hear testimony on 14 bills related to insurance, parity, and opioids.
• I'm here to testify on Bill 2212, An Act to Patient Opioid Notification.
• This bill aims to address the increased prevalence of opioid abuse and overdose across the risk.
• We're preventing mental health needs from getting to crisis level, and we're preventing patients from

Committee: Joint Joint Committee on Mental Health, Substance Use and Recovery

Keywords: 995, all

Summary: The Joint Committee on Mental Health, Substance Use and Recovery held a public hearing on 14 bills focused on insurance, parity, opioids, behavioral health access, and mental health system reform. Chair Mindy Domb and Vice Chair Robyn Kennedy outlined hearing procedures and noted the committee would accept written testimony. The hearing featured testimony from legislators, providers, advocates, and behavioral health organizations, with most speakers urging favorable reports on the bills they addressed. A major topic was psychiatric collaborative care, including H. 222/S. 1390, which would raise reimbursement for collaborative care codes to at least Medicare levels and allow billing outside the MassHealth primary care subcapitation model. Supporters said the model improves access, outcomes, and cost savings by embedding behavioral health in primary care, and several witnesses described successful implementation in practices and schools. Committee members asked questions about how the model works, what specialties use it, barriers to adoption, and whether copays, deductibles, and subcapitation rules should be changed. Witnesses also supported related innovation legislation, including H. 2224, which would create a mental health innovation fund and support nontraditional trauma-healing approaches. Other bills discussed included H. 2212, which would require prescribers to discuss opioid and pain-medication risks, alternatives, and addiction/overdose concerns with patients or guardians; H. 2232 and H. 2233, which would address equitable payment and equitable access for behavioral health providers serving MassHealth patients; and S. 1406, which would add opioid maintenance treatment information to MassPAT and allow patient-authorized access to that information. Witnesses also strongly backed S. 1399, which would set targets to increase behavioral health spending within the overall health care cost benchmark, arguing that Massachusetts underinvests in behavioral health and that greater investment could reduce emergency, hospitalization, homelessness, and criminal justice costs. No votes were taken; the hearing concluded after testimony and committee questions.

Transcript Highlights:

• That is through Brandeis, and I direct the opioid policy research collaborative there.
• I also co-direct the opioids and overdose work at Rhode Island Hospital and I'm at Brown.
• That is through Brandeis, and I direct the opioid policy research collaborative there.
• I also co-direct the opioids and overdose work at Rhode Island Hospital, and I'm at Brown.
• In a retrospective analysis of patients who were identified with opioid-related disorders and who were

Keywords: 995, all

Summary: The Special Commission on Xylazine convened its second meeting, approved the minutes from its June 23 meeting, and reviewed its timeline and working groups. The co-chairs said the commission’s final report is due to the House and Senate clerks by March 30, 2026, and outlined three working groups focused on regulation/oversight of xylazine, treatment and outreach for exposed patients, and education/training for first responders, clinicians, treatment providers, and people who use substances. Staff will schedule working group meetings, with group presentations planned for December 11, followed by commission meetings in February and March to review and finalize the draft report. Public comment centered on research and practical responses to xylazine contamination in the drug supply. Dr. Tracy Green of Brandeis reviewed recent studies showing severe xylazine-related wounds and amputations in Philadelphia, withdrawal symptoms, the value of wound identification tools, and the usefulness of drug checking in detecting xylazine even when users did not suspect it was present. She urged expanded low-barrier wound care, more access to medications for opioid use disorder, overdose prevention sites, housing, and trauma-informed care, while cautioning that stricter controls could push the market toward other dangerous alpha-2 substances. Commissioners asked about early wound identification, dilution/cutting strategies, supplier engagement, and how to reduce stigma and improve treatment access. Tia Johnson of Boston Medical Center and Boston Health Care for the Homeless testified that xylazine contamination still requires naloxone for overdose response, but sedation can last longer and may require low-dose naloxone, oxygen support, and low-threshold monitoring spaces. She emphasized that xylazine-associated wounds can heal with consistent care, but patients often lose access to services when sent to hospitals unnecessarily. Commissioners discussed reimbursement barriers, especially in MassHealth and behavioral health settings, and the need for wound care to be available within detox and treatment programs rather than requiring transfers. The meeting ended with agreement to continue working group planning and adjournment.

Transcript Highlights:

• The Centers for Disease Control and Prevention reports that synthetic opioids, primarily fentanyl, accounted
• The Centers for Disease Control and Prevention reports that synthetic opioids, primarily fentanyl, accounted
• Every state has received billions of dollars in opioid settlement money, and prevention is one of the
• Prevention is something we really need to work.
• We need to have prevention. Prevention is key.

Committee: House Special Committee on Intergovernmental Affairs

Keywords: 959, house, all

Transcript Highlights:

• It goes right to your opioid receptors. It gives you a euphoric high.
• opioids.
• opioids.
• Kratom binds to the opioid receptors in the body.
• It doesn't prevent them from committing it.

Bills: HB2205 , HB2265 , HB2413 , HB2415 , HB2418 , HB2495 , HB2589 , HB2661 , HB2720 , HB2771 , HB2833 , HB2870

Committee: House Judiciary

Keywords: criminal damage, trespassing, critical facilities, felony, Arizona Revised Statutes, court fees, public defender, criminal justice, legal aid, indigent defense, appeals, administrative assessments, sex offender, electronic monitoring, registration, public safety, youth protection, Kratom, narcotic drugs, regulation

Transcript Highlights:

• Our removal being necessary to prevent imminent physical harm. D.C.Y.F.
• This is EMS response statewide to opioid overdoses.
• I often go to the state opioid overdose dashboard or a county.
• Two-thirds, over two-thirds, 68 percent, were opioid-related. A third were not opioid-related.
• Involving opioid use and a child under three.

Summary: The Senate Human Services Committee held a work session on child welfare dependency, focusing on implementation of HB 1227 (Keeping Families Together) and SB 6109 (the fentanyl response bill), along with related data and system updates. DCYF first reviewed the dependency process, explaining intake, shelter care, fact-finding, disposition, and review hearings, and emphasized that removal standards are separate from service provision and that children may be in-home or out-of-home at different stages. DCYF said 1227 raised the removal threshold to imminent physical harm and strengthened kin placement, with nearly 60% of children now placed with relatives or suitable others. The department also said 6109 directs courts to give great weight to fentanyl’s lethality and added legal liaisons to support staff in court preparation. DCYF presented data showing that entries into out-of-home care declined after 1227 but rose again after 6109, returning close to pre-1227 levels. The agency also reported a sharp increase in reviewable critical incidents in 2022-2025, especially near-fatalities, which it linked to the opioid and fentanyl crisis, parental stress, and system complexity. DCYF said it has responded with statewide Safe Child Councils, staff consultations, hotspot monitoring, and additional training, and noted that some contracted services authorized under 6109 were not implemented because of fiscal constraints. Senators asked about where children are in the process, who participates in court, the timing of data releases, age breakdowns, and geographic hotspots. Advocates and lived-experience witnesses from LCYC and a family intervention clinic argued that 1227 has not prevented courts from removing children when necessary and said the law appropriately requires the state to show a causal link between home conditions and risk. They said 6109 appropriately highlights fentanyl’s danger, but stressed that the larger issue is lack of prevention and treatment resources, inconsistent county-by-county practice, and insufficient supports such as inpatient beds, family treatment, housing, transportation, and third-party safety plan participants. A parent ally described how early support, peer guidance, and kin placement helped her achieve recovery and stability after losing parental rights in an earlier case. The committee also heard an update on SB 6068 from the Administrative Office of the Courts and K Implementation and Evaluation. The report identified 15 dimensions of relational permanency and child well-being, found that some data already exist while other measures need development, and recommended a phased data collection plan, a restored data-sharing agreement between AOC and DCYF, and a standing cross-agency work group. AOC said its dependency data system lapsed when the prior agreement expired in June 2025 and needs to be rebuilt. The meeting also included a brief update on bridge housing for youth exiting inpatient treatment, with presenters saying two programs are now open, one in King County and one in Spokane, and a short introduction to juvenile rehabilitation capacity updates before the transcript ended.

Transcript Highlights:

• These allow a 10-week time frame for non-residential opioid treatment programs, treatment plan review
• Section 25 from the DHS policy bill requires an opioid treatment program to meet statutory and regulatory
• requirements for dispensing by a practitioner. policy bill for opioid treatment programs removes the
• study and the work done to develop on the first and the most comprehensive study in the U.S. plans to prevent
• services, which includes mental health therapy, chemical dependency counseling, education, and prevention

Bills: HF2115 , HF2276 , HF1644 , HF99 , HF2068 , HF2707 , HF2704 , HF2406 , HF1674 , HF1579

Committee: House Human Services Finance and Policy

Keywords: human services, aging services, disability services, behavioral health, long-term care, nursing home, nursing facility, assisted living, waiver services, medical assistance, Medicaid, case mix reimbursement, PDPM, RUG, direct care and treatment, developmental disabilities, day services, positive support, guardian, conservator

Transcript Highlights:

• </c><00:20:51.039><c> treatment</c> bill requires an opioid treatment bill requires an opioid treatment
• </c><00:21:00.080><c> treatment</c> policy bill for opioid treatment policy bill for opioid treatment
• When I came into the legislature, I was the vice chair of the preventing homelessness committee.
• In addition, we're prevention programs.
• </c> local housing and homeless prevention local housing and homeless prevention dollars.<01:44:58.800

Bills: HF2115 , HF2276 , HF1644 , HF99 , HF2068 , HF2707 , HF2704 , HF2406 , HF1674 , HF1579

Committee: House Human Services Finance and Policy

Keywords: human services, aging services, disability services, behavioral health, long-term care, nursing home, nursing facility, assisted living, waiver services, medical assistance, Medicaid, case mix reimbursement, PDPM, RUG, direct care and treatment, developmental disabilities, day services, positive support, guardian, conservator

Transcript Highlights:

• Study overdose prevention centers. Thank you, Senator Charlie.
• We have fewer people being prescribed opioids.
• We have fewer people being prescribed opioids.
• So that was a real big push. less strength of opioids, right?
• So, and one of those would be overdose prevention centers.

Summary: The committee first took up House Bill 12, the physical therapy licensure compact. The sponsor and supporters said the bill would increase access to care and help recruit physical therapists in New Mexico, especially in rural areas and for neurodivergent patients. Support came from the Greater Albuquerque Chamber of Commerce, Desert States Physical Therapy Network, Think New Mexico, the state Health Care Authority, and Americans for Autism Advocacy. A trial lawyer raised concerns about immunity, venue, and loser-pays language, and committee members discussed whether New Mexico-specific amendments would be accepted by the compact commission. Two amendments were adopted, including clarifying language on background checks, data, federal court standing, and repeal procedures, plus an immunity-related amendment. The bill was then reported out with a 9-0 due pass recommendation. The committee then considered House Bill 10, the physician assistant interstate compact. Supporters again emphasized workforce shortages, telehealth access, and the need to join the compact to qualify for Rural Health Transformation Program funding. The Health Care Authority said the compact was part of New Mexico’s commitments tied to federal funding, and a trial lawyer again raised concerns about loser-pays language. Two amendments were adopted to clarify New Mexico’s authority over reproductive and gender-affirming care issues, confidentiality of New Mexico licensee data, joint investigations, and contingent repeal procedures. After discussion about malpractice exposure, oversight, and the need for compact commission approval of language changes, the bill received an 8-0 due pass recommendation. House Bill 34, dealing with school nurse licensure provisions, was presented as a cleanup bill to clarify implementation issues from last session. The changes would add charter schools, align contract language with teacher contracts, and adjust supervision and evaluation rules for tiered school nurses in small districts. The New Mexico School Nurses Association supported the bill, and it passed unanimously with an 8-0 due pass recommendation. The committee also heard Senate Memorial 21, which would direct the Department of Health to study overdose prevention centers and other harm reduction strategies. Supporters from the ACLU, All Safe New Mexico, the Drug Policy Alliance, and Families and Youth Innovations Plus argued that New Mexico’s overdose crisis remains severe and that evidence-based interventions could save lives and connect people to treatment. The Department of Health provided background on overdose trends and said it was neutral but available for technical questions. After discussion about fentanyl trends, drug prices, and public health approaches, the memorial was approved on a 7-1 due pass vote. The committee also announced that Senate Bill 130 would be rolled over to Sunday’s meeting because a new substitute needed review.

Transcript Highlights:

• The Centers for Disease Control and Prevention reports that synthetic opioids, primarily fentanyl, accounted
• The Centers for Disease Control and Prevention reports that synthetic opioids, primarily fentanyl, accounted
• Every state has received billions of dollars in opioid settlement money, and prevention is one of the
• Prevention is something we really need to work on.
• We need to have prevention. Prevention is key.

Committee: House Special Committee on Intergovernmental Affairs

Summary: The committee first took up House Bill 2901 in executive session. After a brief explanation from the bill sponsor, the committee adopted a House Committee amendment ending in 0.07 that set a five-year expiration date and clarified where reports must be filed. The committee then rolled the amendment into a substitute and voted the House Committee substitute do pass by a roll call of 13 ayes and 0 noes. The committee then heard House Bill 3000, which would fix the signature threshold for petition-driven audits by tying the required number of signatures to the gubernatorial election in effect when the petition process begins, rather than when signatures are submitted. The sponsor and the State Auditor’s office said the change would prevent the required number from shifting during the petition period and provide consistency. No vote was taken on the bill during the hearing. House Bill 313 was then heard, a fentanyl-poisoning response bill that would require naloxone in public buildings, designate October as Fentanyl Poisoning Awareness Month, require fentanyl education for students in grades 6 through 12, and require training and investigation procedures for law enforcement in drug-related deaths. The sponsor and multiple family members who lost loved ones to fentanyl strongly supported the bill, emphasizing prevention, access to Narcan, and more thorough death investigations. Committee members generally expressed support, raised questions about the definition of public buildings, school implementation, and funding, and testimony suggested opioid settlement money as a possible source. No committee action was taken on HB 313 in the transcript.

Transcript Highlights:

• to apply more strict controls than are applied to opioids.
• I am supportive of improving access to non-opioid medication options.
• One of the PCAs was new and stole her opioid medication.
• Medicare for All prevents municipalities from going broke.
• than opioids.

Committee: Joint Joint Committee on Health Care Financing

Keywords: 995, all

Summary: The Joint Committee on Health Care Financing held a public hearing on 16 bills, with the chairs noting a busy legislative day and asking speakers to keep testimony brief. The committee first heard testimony on Senate 860/House 1405, the Medicare for All bill, with Sen. Jamie Eldridge and many advocates, clinicians, municipal officials, and patients arguing that a single-payer system would make care a right, reduce administrative waste, lower costs, and protect residents from rising premiums, medical debt, and hospital closures. Several speakers cited the Steward hospital crisis, affordability problems, and polling or ballot questions showing public support for single-payer coverage. No vote was taken during the hearing. The committee then took testimony on S. 863, a bill on non-opioid options for chronic pain. Pain specialists, patients, and advocates said the bill would improve care coordination for MassHealth members, expand access to non-opioid medications, require provider education, and collect data on chronic pain. Testifiers described long delays in diagnosis and treatment, stigma toward pain patients, and the need for multidisciplinary care and transportation support. Again, the committee heard testimony only and took no action. A large portion of the hearing focused on H. 1360/S. 869, which would prevent discrimination against people with disabilities in health care. Disability advocates, clinicians, and patients described being denied or delayed care, pressured into DNR orders, or treated based on assumptions about quality of life rather than medical facts. Speakers referenced COVID-era crisis standards of care, discriminatory metrics, and personal stories involving canceled procedures, inadequate accommodations, and poor treatment in hospitals. Committee members thanked speakers for their testimony and said they would review the bill and its implications, but no vote was announced. The committee also heard testimony on H. 1399, an individual Medicare marketplace option for municipal retirees, where supporters said it would give cities and towns a lower-cost alternative for retiree health benefits through HRAs and individual Medicare plans. The hearing then returned to Medicare for All testimony, with additional supporters repeating arguments about cost, access, municipal budget pressure, and the need for global budgeting and universal coverage. The transcript ends with continued testimony and no recorded committee vote or final action on any bill.

Transcript Highlights:

• Because you've been off opioids for a while, your tolerance for opioids is way down, and that's what
• The intention of those agreements was to reduce the opioid overdose crisis.
• This is an unfortunate result of the opioid settlement agreement.
• Prevent last-minute emergencies and gaps in care.
• We have to talk about the opioid settlement program.

Committee: House House Health & Human Services

Transcript Highlights:

• This situation was entirely preventable. These situations are not rare.
• That's the standard of care and medication for patients with opioid use disorders.
• HB137 has potential to remove one of the most significant and preventable barriers to care.
• Opioid withdrawal treatment should not be any exception.
• “HB 137 will help us move the needle on opioid overdose. Please pass it. Thank you so much.”

Summary: The committee first took up House Bill 213, which would allow optometrists to perform three specific laser procedures. The sponsor presented a committee substitute adding 32 hours of approved advanced training, supervised live-patient practice, adverse-event reporting, and other accountability measures. Supporters argued the bill would improve access to care, while the New Mexico Medical Board opposed it, citing patient-safety concerns and the much greater training required of ophthalmologists. After debate, the committee adopted the substitute and passed the bill 6-3. The committee then considered House Bill 65, renamed the Foster Care Plus pilot program. The substitute changed the bill to require clinical assessment instead of CAN assessment, added reporting to the Legislature and LFC, and clarified contracting with clinical experts. CYFD officials said the $2.5 million request, combined with existing growth funding, would support more children, staff, foster-parent stipends, and related services, and that the program is already being implemented with help from Oklahoma-based experts. Some members remained concerned about cost, staffing, and whether the program could be sustained, but the committee adopted the substitute and passed the bill 8-1. House Bill 127, on expedited medical licensure, was amended to create a provisional pathway for internationally trained physicians, require a job offer and benchmarks before full licensure, and establish a telemedicine registry. The Medical Board supported the amended bill, while public commenters emphasized physician shortages and access to care. The committee adopted the amendment and passed the bill. House Bill 128, which updates firefighter occupational disease and disablement presumptions to add cancers and other changes, drew strong support from firefighters, labor, and workers’ compensation officials; the committee adopted the amendment and passed the bill. House Bill 156, which removes the sunset on the state’s authority to set vaccine guidelines and continue its vaccine program, also passed after supporters argued it preserves access and opponents raised broader vaccine-policy concerns. The committee then began hearing House Bill 137, a buprenorphine access bill, with the sponsor and advocates describing pharmacy supply barriers and a committee substitute aimed at setting minimum stock standards, requiring distributor reporting, and avoiding fines on pharmacies.

Transcript Highlights:

• And if an opioid uh for that person.
• /c> CDC developed opioid prescribing CDC developed opioid prescribing guidelines<00:22:04.720><c> in<
• </c> guidelines in response to the opioid guidelines in response to the opioid crisis,<00:22:06.960><
• . prevention. prevention.
• It's preventive.

Committee: Senate Commerce and Consumer Protection

Keywords: 1187, senate, all

Bills: HB1163 , HB2113 , HB2333 , HB2411 , HB2583 , HB1613 , HB1614 , HB2590 , HB1950 , HB1603 , HB1707 , HB1832 , HB2119 , HB2155 , HB2594 , HB2595 , HB1929 , HB2015 , HB2207 , HB1619 , HB1667 , HB1984 , HB2140 , HB2097 , HB1957 , HB2503 , HB2581 , HB1520 , SCR55 , SR53

Keywords: commercial drivers license, non-domiciled, federal regulations, commercial learner's permit, citizenship, lawful residency, Department of Transportation, Kainahola Stream, flood prevention, vegetation removal, appropriation, natural resources, transportation, airport special districts, penalties, Hawaii, aeronautics law, public safety, workforce development, sector partnerships

Transcript Highlights:

• Creating a criminal penalty for operating without a license will help deter exploitation and prevent
• We can tailor those prevention programs for whatever group we are working with.
• Drug antagonist medications are used to block the effects of opioids such as heroin and fentanyl to prevent
• school district, and non-profits to address the opioid epidemic that our communities are facing.
• overdoses through statewide opioid antagonistic distribution strategies.

Bills: HB35 , HB138 , HB754 , HB1314 , HB1612 , HB2254 , HB2510 , HB2789 , HB3560 , HB3597 , HB4224 , HB4273 , HB4643 , HB4783 , HB138

Committee: Senate Health & Human Services

Keywords: peer support, first responders, mental health, confidentiality, emergency services, health impact analysis, cost analysis, coverage mandates, health insurance, legislative analysis, health care data, human trafficking, trafficking prevention, medical assistant training, health care facilities, hospital compliance, clinic compliance, anti-retaliation, whistleblower protection, employee reporting

Transcript Highlights:

• Significantly weaken the law's most powerful proactive and preventative effects.
• It's the perfect form of prevention. There's a lot of disease with the disease.
• We have real problems in this country with opioid addiction.
• Nodding, too, in terms of prevention. What is an appropriate age?
• Every year in this country, many of them as a result of fentanyl or opioids.

Committee: Senate Senate Judiciary

Transcript Highlights:

• In a study titled "Opioid overdose knowledge among adolescents and young adults," ...
• overdose—a preventable opioid overdose.
• overdose—a preventable opioid overdose.
• My research has focused extensively on school-based approaches to opioid overdose prevention.
• My research has focused extensively on school-based approaches to opioid overdose prevention and naloxone

Committee: Joint Joint Committee on Higher Education

Keywords: 995, all

Summary: The Joint Committee on Higher Education held its fourth public hearing, opening with remarks about the importance of protecting and expanding access to higher education amid federal disinvestment. The chairs also announced future informational hearings on the impact of federal cuts and on ASAP models. The hearing then focused on several bills, beginning with S. 951/H. 1462, An Act to Support College Students in Recovery, which would require recovery-focused housing on public campuses and expand naloxone access and overdose training. Senator Rausch, medical professionals, students, and advocates testified in support, emphasizing the prevalence of overdose risk among college students, the value of recovery housing, and the need for campus naloxone; committee members asked about implementation details and the existing state pilot program. Deb Schmill and Rep. Tarski gave especially personal testimony in favor of the bill, and the committee discussed broadening the naloxone language to opioid reversal agents. The committee also heard testimony on H. 1461, which would expand MassReconnect scholarships to practical nursing students at vocational and technical schools to help address the long-term care workforce shortage. Rep. Stanley argued that vocational schools graduate more practical nursing students than community colleges and serve many low-income students in areas without nearby community college programs. The committee then took up H. 1433, which would require public higher education institutions to accept IEPs and 504 plans as sufficient documentation for disability accommodations. Advocates from the National Center for Learning Disabilities described the high cost and burden of repeat testing, the lifelong nature of disabilities, and the need for more uniform access across campuses; committee members raised questions about documentation freshness, campus autonomy, and how to preserve the integrity of accommodations. Later, the committee heard S. 919/H. 1454 on modernizing the Community College Endowment Match Program so community colleges could receive state matching funds for current-use donations as well as endowments and capital gifts. Community college foundation leaders said the change would help fund immediate student needs such as food pantries, child care, emergency aid, and equipment. The hearing then moved to faculty-related bills: S. 933 on UMass faculty rights and tenure transparency, S. 930/H. 3948 on contingent faculty rights and career advancement, and S. 940/H. 1429 on an Adjunct Bill of Rights. Testimony from faculty and union representatives focused on low pay, lack of benefits, job insecurity, and the need for clearer pathways to full-time positions and fairer treatment for adjuncts who teach large shares of courses. No votes were taken during the hearing; the committee primarily received testimony and asked clarifying questions.

Transcript Highlights:

• Although people may be dying from opioid use, this does not mean that opioid usage is going down and
• or alcohol. to treat either opioid or alcohol use disorder.
• , and recovery sectors to coordinate opioid response efforts.
• I was just notified last week that we received some opioid settlement dollars.
• A lot of these different programs and also for prevention.

Committee: House Legislative Health & Human Services Committee

Transcript Highlights:

• , and withdrawal symptoms consistent with other opioids.
• Your opioid addict... Your opioid addict removes the cravings.
• And so the reality is, if an opioid addict succumbs to the cravings and starts opioids again, and they
• It's very similar to opioid use disorder. It's very similar to opioid use disorder.
• And I don't know if that's preventable or if that's just part of the chemistry of of of Preventable or

Summary: The working group met for a legislative-only discussion on kratom ahead of a special session, with members agreeing to keep remarks brief and noting a public open house and expert testimony would follow the next week. Staff provided an overview of kratom regulation, describing the substance, its psychoactive effects, reported health risks, federal DEA action on 7-OH, state approaches, and North Dakota’s recent executive action and special session call. Legislators then debated whether the state should prohibit kratom, regulate it, or distinguish between natural kratom and synthetic or concentrated 7-OH products. Several members cited extensive testimony from the 2025 session, including House Bill 1101, which would have scheduled kratom as a Schedule I substance and failed in the House, and House Bill 1566, which evolved into a study. Supporters of regulation emphasized testimony from people who said natural kratom helped with chronic pain or function, while others stressed concerns about addiction, adulterated products, youth access, infant withdrawal, and deaths linked to kratom or 7-OH. Members also discussed enforcement and public health issues, including whether the Good Samaritan law should be updated, how law enforcement would respond under the executive order, and whether withdrawal could drive people toward harder drugs. One member urged a temporary approach until the 2027 session, while others argued the short special session could still address a narrow ban on 7-OH and tighter controls on natural kratom. No votes were taken, and the meeting ended with plans for additional testimony and further legislative hearings during the special session.